Comparative Pharmacology
Head-to-head clinical analysis: IONTOCAINE versus LIDOCAINE HYDROCHLORIDE 0 2 IN DEXTROSE 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IONTOCAINE versus LIDOCAINE HYDROCHLORIDE 0 2 IN DEXTROSE 5.
IONTOCAINE vs LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iontocaine (lidocaine 2% and epinephrine 0.01%) combines a sodium channel blocker (lidocaine) to inhibit nerve impulse propagation, producing local anesthesia, with epinephrine causing vasoconstriction to reduce systemic absorption and prolong effect.
Lidocaine is a local anesthetic that stabilizes neuronal membranes by inhibiting sodium ion influx, thereby blocking initiation and conduction of nerve impulses.
IONTOCAINE is not a recognized drug. No standard dosing available.
1-1.5 mg/kg IV bolus over 2-3 minutes, followed by continuous IV infusion of 1-4 mg/min for ventricular arrhythmias; maximum 3 mg/kg (or 200-300 mg) over 1 hour.
None Documented
None Documented
Terminal elimination half-life is 2.5-3.0 hours; prolonged in renal impairment (up to 6-8 hours).
Terminal elimination half-life: 1.5-2 hours (adults); prolonged in heart failure (up to 4-6 hours) or hepatic impairment (up to 5-7 hours).
Primarily renal excretion of unchanged drug (70-80%) and glucuronide conjugate (15-20%); less than 10% fecal.
Renal: ~90% as metabolites and <10% unchanged. Biliary/fecal: minor (<1%).
Category C
Category A/B
Local Anesthetic
Local Anesthetic / Antiarrhythmic (Class Ib)